Tirzepatide Dual agonist : GLP-1 + GIP Central benchmark for dual incretin research Often discussed in relation to body-weight outcomes, glycaemic control and incretin signalling Single agonist : GLP-1 More selective and mechanistically narrower Common reference point for GLP-1 pathway research Triple agonist : GLP-1 + GIP + glucagon Broader receptor profile than Tirzepatide Often discussed in relation to weight loss, energy expenditure and next-generation multi-pathway metabolic modulation For researchers comparing incretin classes, Tirzepatide often functions as the middle reference point between single-pathway GLP-1 agonists and broader triple-agonist designs
Weight change after GLP-1 discontinuation in US patients living with overweight/obesity or diabetes
Recent studies are showing that GLP-1 usage can help restore metabolic flexibility, so you may be able to maintain your results with proper nutrition, regular exercise, and a gradual adjustment to your dose
FDA scientists flag concerns with peptides, the trendy molecules RFK Jr
The results were significant, showing a reduction in cardiovascular events and deaths in those using GLP-1 receptor agonists compared to patients on other diabetes medications
